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Abstract 
Complete or partial monosomies of the long arm of 
chromosome 5 and/or 17p are common findings in 
myeloid malignancies, particularly in therapy-
related myeloid disorders.  
They usually result from interstitial or terminal 
deletions and less frequently from unbalanced 
rearrangements such as dicentric chromosomes. 
One of the recurring unbalanced translocation in 
myeloid malignancies is the unbalanced dicentric 
translocation dic(5;17)(q11-14;p11-13) that results 
in complete or partial monosomy for the long arm 
of chromosome 5 and the short arm of chromosome  
17. 
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Included are 5q11-14 and 17p11-13 breakpoints 
(breakpoints described at or near the centromeres), 
the related unbalanced der(5)t(5;17) and 
der(17)t(5;17) are not included. 
Figure 1  dic(5;17)(q11.2~13;p11.2~13) G- banding: - Courtesy Ronnie Ghuman and Charles D. Bangs. 
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Clinics and pathology 
Disease 
Chronic myeloproliferative neoplasms and acute 
myeloid leukemia (AML)  
16 patients had a primary myelodysplastic 
syndrome (MDS) (Knapp et al., 1985; Herry et al., 
2007; Lange et al., 2010) or de novo AML (Huret et 
al., 1991; Kwong et al., 1994; Arkesteijn et al., 
1996;  Tosi et al 1996; Wang et al., 1997;  Mrozek  
et al., 2002; Zatkova et al., 2006; Herry et al., 2007; 
Hangai et al., 2013) and 2 patients had chronic 
myelogenous leukemia in advanced phase 
(Hagemeijer et al., 1981; Wang et al., 1997).  23 
patients developed therapy-related MDS (Hatzis et 
al., 1995; Wang et al 1997; Andersen et al., 2005; 
Andersen et al., Andersen et al., 2008) or AML  
(Kerim et al., 1991; Heyn et al., 1994; Wang et al., 
1997; Nakamori et al., 2003; Andersen et al., 2005; 
McNerney et al., 2014) after cytotoxic treatment 
and/or radiotherapy (Table 1). 
 
 
  Sex/Age Diagnosis Karyotype 
1 M/26 CML 
44-45,XY,dic(5;17)(q11;p11),t(9;22),r(18) 
blast crisis  
2 M/57 RAEB 45,XY,dic(5;17)(q11;p11),-7,+8/46,idem,add(18)(q23),+mar 
3 M/69 AML-M2 
45,XY,r(3),dic(5;17)(q14;p13),del(7)(q11),add(9)(p2?),add(9)(q34),-12,-13,i(21)(q10),+mar/90, 
idemx2 
4 M/71 AML-M1 
47,XY,+8/44,XY,-5,-17,-18,+mar/44,XY,dic(5;17)(q11;p11),-18/46,XY,dic(5;17),-18,+mar 
idiopathic myelofibrosis, chemotherapy  
5 M/1 AML 
45,XY,hsr(2)(q22),dic(5;17)(q11;p11),der(7)del(7)(q11)hsr(7)(q11),der(12)t(12;19)(p11;q12),-19,  
+mar 
embryonal rhabdomyosarcoma, chemotherapy, radiotherapy 
6 M/77 AML-M1 47,XY,+14/45,XY,dic(5;17)(q11;p11),dmin/95-96,XXY,-Y,-5,+9,+11,+12,+13,+13, +14,+14,+ 17  
7 F/59 RAEB 
45,XX,dic(5;17)(q11;p11) 
acute promyelocytic leukemia, relapse, chemotherapy 
8 M/45 AML-M1 
46,XY,t(1;15)(p21;q23),t(3;5)(q23;q12),ins(4;12)(q28;p?),dic(5;17)(q11;p11),der(7)t(7;18)(q11;q12) 
t(14;18)(q12;q23),+8,-14,del(18)(q12q23),add(19)(q23), +21  
9 F/63 AML 46,XX,dic(5;17)(q11;p11),-7,der(10)t(10;19)(p11;q11),-19,+2mar 
10 M/75 AML 46,XY,-3,dic(5;17)(q11;p11),del(7)(q22q?),+8,+11,-15,+mar 
11 M/66 AML-M6 
43,XY,der(5)t(5;12)(q13;q14),dic(5;17)(q13;p11),-7,dup(9)(q21q12),-12,-15, add(16)(q13), 
add(17)(p11),-18, +add(21)(p11),+mar/44,idem,+13 
12 F/64 MDS 
45,XX,-7/45,XX,dic(5;17)(q11;p11)/44,XX,dic(5;17),der(7)t(7;13)(q11;q14), add(13)(q14),-17/ 
44,XX,-3, dic(5;17),der(7)t(3;7)(p14;q32)/44,XX,-3,der(5)t (5;7)(q11;p1?5),dic(5;17), 
der(7)t(7;16)(p1?5;p13)t(3;7), der(16;17)t(16;17)(p13;p11)ins(16;5)(p13;q11q11),add(21)(q22) 
adenocarcinoma, chemotherapy, radiotherapy  
13 F/50 AML 
45,XX,dic(5;17)(q13;p11),inv(5)(p13q11)/46,idem,+8/44,idem,-11,add(16)(p13) 
,der(19)t(11;19)(q11q25;p13) add(11)(q11) 
 multiple myeloma, chemotherapy 




15 F/73 AML 
43,XX,dic(3;22)(p21;p11),dic(5;17)(q11;p11),-7,+8,add(12)(p13),add(14)(p11), -16/44,idem,+mar 
adenocarcinoma, radiotherapy 
16 F/48 MDS 
46,XX,t(8;17)(p11;q22) or t(8;17)(p21;q23)/46,XX,del(7)(q22q34)/46,XX,t(2;18)(p21;p11)/  
46,XX,t(2;12)(q11;q21-22),t(11;17)(q13;q25)/45,XX,del(1) (p34p36),dic(5;17)(q13;p11),+8,-18 
follicular lymphoma, chemotherapy, radiotherapy 
17 M/55 MDS 
44,XY,dic(5;17)(q13;p11),dic(19;20)(p13;q11)/45,idem,+mar 
Hodgkin disease, chemotherapy 
18 F/81 MDS 
47,XX,del(3)(p21p24),dic(5;17)(q13;p11),+8,+22/48,idem,+X 
adenocarcinoma, radiotherapy 
19 M/58 MDS 
45,XY,dic(5;17)(q11;p11),r(7)(p2?2q1?1)/45,idem,dic(5;17),i(9)(p10),del(13)(q12q14)/43,XY, 
dic(5;17),-7, dic(9;18)(q13;p11)/44,XY,dic(5;17),-7/46,XY,del(11)(q14q23) 
chronic lymphocytic leukemia, chemotherapy  
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21 M/57 AML-M7 47,XY,dic(5;17)(q11;p11),-7,-13,add(19)(p13),+4mar 




23 M/25 AML 
44,XY,del(3)(p13),dic(5;17)(q11;p11),-7 
Hodgkin disease, chemotherapy, radiotherapy 
24 M/8 AML 
45,XY,dic(5;17)(q11;p11),del(7)(q22q35)/46,idem,+21/44,idem,der(11;21)t(11;21)(p15;p13) 
ins(11;?)(p15;?) add(11)(q22) 
rhabdomyosarcoma, chemotherapy, radiotherapy 
















Wegeners granulomatosis, chemotherapy 
28 M/69 MDS 
46,X,t(Y;16)(q12;q?),del(3)(p24p?),del(5)(q31q31),dic(5;17)(q11;p11),dup(19)(q?),+del(21)(q21)/ 
48,idem,+18, +19,-dup(19),+22 
Hodgkin disease, chemotherapy, radiotherapy 









31 M/73 AML 
44,XY,dic(5;17)(q11;p11),der(6)del(6)(p?)del(6)(q?),dup(6)(q?),-7,dup(8)(p?),ins(9;5)(q34;q31q31) 
Hodgkin disease, chemotherapy, radiotherapy 




Hodgkin disease, chemotherapy, radiotherapy  




Hodgkin disease, chemotherapy 
34 M/72 AML-M1 
47-49,XY,der(2;7)dic(2;7)(p23;q11)t(2;12)(q33;q11),dic(5;17)(q11;p12),+8,+r(11)x3, 
der(12)t(2;12)(p23;q11),+13 
35 F/32 MDS 45,XX,dic(5;17)(q11;p11),-7,+r/45,idem,add(14)(p11) 
36 F/79 MDS 46,XX,dic(5;7)(q11;p11),idic(5)(q11),r(5),?dic(7;8)(q31;p22),?dic(12;17)(p12;q22) 
37 M/69 AML-M2 46,XY,dic(5;17)(q11;p11),-7,+add(11)(q25),+13,del(13)(q31)x2,-16,-17,-18, +3mar 
38 M/69 MDS 
46,X,t(Y;16)(q12;q?),del(3)(p24p?),del(5)(q13q31),dic(5;17)(q11;p11),dup(19)(q?),+del(21)(q21)/ 
48,idem,+18,+19,-dup(19),+22 
Hodgkin disease, chemotherapy, radiotherapy 
39 M/73 RAEB 44-45,XY,dic(5;17)(q11;p11),+8,-13,-21,+1-2mar/45-47,idem,+13,t(15;18)(q10;q10),+i(21)(q10) 
40 M/79 AML-M6 44,XY,add(2)(q21),dic(5;17)(q13;p11),-7,+8,add(12)(p11),-15,-16,+mar 
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41 M/39 AML 
45,XY,-3,r(5)(p14q11),-7,+der(19)t(3;19)(q2?5;q13)/44,XY,-3,dic(5;17)(q12;p11),-7,+mar/ 44,XY, 
t(3;15) (p2?3;q15),dic(5;12)(q12;p11),-7,add(10)(p13) 
squamous cell carcinoma, chemotherapy, radiotherapy 
Table 1. Reported patients with dic(5;17)(q11-14;p11-13). 
Abbreviations: CML, chronic myeloid leukemia; RAEB, Refractory anemia with excess of blasts; AML-M2, Acute myeloblastic 
leukemia with maturation (FAB type M2); AML-M1, Acute myeloblastic leukemia without maturation (FAB type M1); AML, Acute  
myeloid leukemia, NOS; AML-M6, Acute erythroleukemia (FAB type M6); MDS, Myelodysplastic  syndrome; AML-M7, Acute 
megakaryoblastic leukemia (FAB type M7). 1. Hagemeijer et al., 1981; 2. Knapp et al.,  1985; 3. Huret et al., 1991; 4. Kerim et 
al., 1991; 5. Heyn et al., 1994; 6.  Kwong et al., 1994; 7. Hatzis et al., 1995; 8. Arkesteijn et al., 1996;  9-10. Tosi et al., 1996; 11-
24. Wang et al.,  1997;  25.Mrozek et al., 2002; 26.  Nakamori et al., 2003; 27.Andersen et al., 2005; 28-33.Andersen et al.,
2005;  34. Zatkova et al., 2006; 35-37. Herry et al., 2007; 38. Andersen et al., 2008;  39.Lange et al., 2010; 40. Hangai et al., 
2013;  41. McNerney  et al., 2014. 
Phenotype/cell stem origin 
Phenotype / cell stem origin de novo and therapy 
related myeloid malignancies. 
Epidemiology 
29 male and 12 female patients (sex ratio 2.4) aged 
1 to 86 years (median age 63 years).  
There were 2 pediatric cases (aged 1 and 8 years), 
both of them developed AML after therapy for 
rhabdomyosarcoma. 
Prognosis 
Patients with 5q and/or 17p deletions and complex 
karyotypes represent an unfavorable cytogenetic 
prognostic category, particularly when the disorder 
is related to previous cytotoxic therapy. 
Cytogenetics 
Cytogenetics morphological 
Presents as 1 normal chromosome 5 and 17 and a 
dic(5;17) chromosome that contains the short arm 
of chromosome 5, the long arm of chromosome 17 
and centromeres of both chromosomes; breakpoints 
at or near the centromeres may be difficult to 
ascertain, the most common described breakpoints 
were q11 on chromosome 5 and p11 on 17p, 
reported in 31 out of 41 patients.  
Combining karyotyping with fluorescence in situ 
hybridization of centromere-specific probes for 
chromosomes 5 and 17 allows precise breakpoint 
definition and confirm the presence of both 
centromeres. 
Additional anomalies 
Sole anomaly in 1 MDS patient previously treated 
for acute promyelocytic leukemia and found in 
association with increased karyotype complexity in 
most of the cases.  
The most commonly observed anomaly was 
monosomy 7, observed in 19, while 7q deletion was 
found in 5 patients. Monosomy 5/5q- was found in 
4 and +8 in 10 patients. 




Deletion of 5q and 17p through formation of an 
unbalanced dicentric rearrangement is a non-
random event in myeloid malignancies, particularly 
in therapy-related disorders. dic(5;17)(q11-14;p11-
13) result in partial monosomy for 5q and 17p
leading to altered gene dosages, affecting tumor 
suppressor genes. The key mechanism might be the 
combined loss of tumor suppressor genes in 5q and 
17p containing the TP53 gene. It is likely that TP53 
loss that is frequently accompanied by inactivating 
mutations in the remaining TP53 allele (Wang et 
al., 1997) represent one of the instigators of the 
genome instability that is manifested by complex 
karyotypes. Highly complex rearrangements 
containing unbalanced translocations, ring 
chromosomes, insertions, marker chromosomes, 
homogeneously staining regions, dicentric 
chromosomes and cytogenetically unrelated clones 
were overrepresented in patients with therapy-
related myeloid malignancies, indicative of the role 
of mutagenic effect of previous therapy. The 
probable sequence of genetic events is unclear; 
however dic(5;17) usually presents with additional 
common anomalies such as monosomy 7/7q or 5/5q 
and trisomy 8, therefore the formation of dic(5;17) 
likely represent a therapy-induced abnormality that 
occurred during the multistep process of 
leukemogenesis 
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